Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
Kalkine Media ASX Share Market News & Research

The Share Price Of Factor Therapeutics Remains Unaffected By The Retirement Of The Chief Executive Officer

3 min read | January 25, 2019 12:17 PM SAST | By Team Kalkine Media
The Share Price Of Factor Therapeutics Remains Unaffected By The Retirement Of The Chief Executive Officer

Recent News

Make Kalkine Media
My Trusted Source

Google Source

Biotechnology Company, Factor Therapeutics Limited (ASX:FTT) today made an announcement regarding a change in the Company's management. In the announcement, the company has informed that Dr. Rosalind Wilson has completed her tenure as Chief Executive Officer (CEO) of the company. However, she will continue to work with the company as a part-time consultant to assist the Company’s future plans.

While thanking Dr. Rosalind Wilson for her contribution and commitment to the Company, the company’s Chairman Dr. Cherrell Hirst said, moving forward, the management of the company is pleased to be able to call on her experience and corporate knowledge as the company formulate plans for the future.Â

Dr. Rosalind Wilson joined the company in mid-2017 and under her leadership, the company completed the Phase 2 clinical programme in venous leg ulcer healing and the limited expansion of the Company’s pipeline. The Phase 2 clinical trial was conducted to determine whether VF001 could improve healing for patients with venous leg ulcers and the results have demonstrated that VF001 does not improve the healing for patients with venous leg ulcers.

Dr. Wilson has been working with the team and the Board to ensure an orderly completion of the Company’s previous research and development activities. Earlier in December 2018, the company announced the retirement of Dr. Robert Ryan from the Company’s Board.

At the end of the September quarter, the Company had cash reserves of $4.047 million. Quarterly operating expenditure during the September quarter was $2.436 million which was in line with forecasts, with $1.705 million on direct R&D activities.

During the September quarter, the company announced that, in association with US researchers, it had defined the key parameters of a pilot clinical study of VF001 for diabetic foot ulcer (DFU), with the aim of generating data to form the foundation of Phase 2/3 clinical program. Subsequent to the end of the September quarter, the Company announced that it had appointed Taylor Collison Limited as Transaction Advisor for assisting in the ongoing partnering discussions and advise on transactional options following a successful readout from the Phase 2 VLU clinical trial.

For the six months ended 30 June 2018, the company’s Revenue from continuing operations decreased by -88.81 percent to $197,261 as compared to the previous corresponding year. The company reported a loss after income tax for the half-year of $4.756 million which was 13.21% lower than the previous corresponding year. During the half year, the company received the R&D tax incentive of $1,226,202.

Meanwhile, in the past six months, the share price of the company decreased by 95.45 percent as on 24 January 2019. FTT’s shares traded at $0.002 with a market capitalization of circa $1.67 million as on 25 January 2019.

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.